Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors

Hormone and Metabolic Research

Volumn 43, Issue 12, 2011, Pages 844-853

  Pavel, M E ^a   Wiedenmann, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis inhibitors; Everolimus; Sunitinib; Targeted drugs; Tyrosine kinase inhibitors

Indexed keywords

2 METHOXYESTRADIOL; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DALOTUZUMAB; DOXORUBICIN; ENDOSTATIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GANITUMAB; GEFITINIB; MOTESANIB; OCTREOTIDE; PANITUMUMAB; PASIREOTIDE; PAZOPANIB; SOGRAZEPIDE; SORAFENIB; SUNITINIB; TELOTRISTAT ETHYL; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ASTHENIA; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOID; COLON CANCER; CUSHING DISEASE; DIARRHEA; DIGESTIVE SYSTEM TUMOR; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; ENDOCRINE TUMOR; FATIGUE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS ISLET CELL CARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RECURRENT CANCER; REVIEW; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

MAMMALIA;

EID: 82155166239     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1291368     Document Type: Review

References (71)

1. van Zwieten P A, Blauw G J, van Brummelen P. Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs. Clin Physiol Biochem: 1990; 8 03 1 18
2. Vinik A I, Tsai S T, Moattari A R, Cheung P, Eckhauser F E, Cho K. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med: 1986; 81 23 40
3. Wood S M, Kraenzlin M E, Adrian T E, Bloom S R. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: symptomatic and peptide responses. Gut: 1985; 26 438 444 (Pubitemid 15064706)
4. berg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med: 1983; 309 129 133 (Pubitemid 13069520)
5. Moertel C G, Lefkopoulo M, Lipsitz S, Hahn R G, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med: 1992; 326 519 523
6. Turner N C, Strauss S J, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent R H, Caplin M E, Meyer T. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer: 2010; 102 1106 1112
7. Fjallskog M L, Janson E T, Falkmer U G, Vatn M H, Oberg K E, Eriksson B K. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology: 2008; 88 53 58 (Pubitemid 352009119)
8. Otte A, Jermann E, Behe M, Goetze M, Bucher H C, Roser H W, Heppeler A, Mueller-Brand J, Maecke H R. DOTATOC a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med: 1997; 24 792 795 (Pubitemid 27356860)
9. Gurusamy K S, Ramamoorthy R, Sharma D, Davidson B R. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev: 2009; 2 CD007060
10. Gurusamy K S, Pamecha V, Sharma D, Davidson B R. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev: 2009; 1 CD007118
11. Eriksson B, Klppel G, Krenning E, Ahlman H, Plckinger U, Wiedenmann B, Arnold R, Auernhammer C, Krner M, Rindi G, Wildi S. and all other Frascati Consensus Conference participants Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors Well Differentiated Jejunal-Ileal Tumor/Carcinoma. Neuroendocrinology: 2008; 87 8 19 (Pubitemid 350308290)
12. Modlin I M, Pavel M E, Kidd M, Gustafsson B. Review Article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Alim Pharmacol Therap: 2010; 31 169 188
13. Rinke A, Mller H, Schade-Brittinger C, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, Pape U, Blker M, Harder J, Arnold C, Gress T, Arnold R. PROMID study group Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol: 2009; 28 4656 4663
14. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, Ferdeghini M, Pederzoli P, Scarpa A, Falconi M. Butturini Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer: 2006; 13 1213 1221 (Pubitemid 46212575)
15. Faiss S, Pape U F, Bohmig M, Drffel Y, Mansmann U, Golder W, Riecken E O, Wiedenmann B. and International Lanreotide and Interferon Alfa Study Group Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol: 2003; 21 2689 2696 (Pubitemid 46606312)
16. Arnold R, Rinke A, Klose K J, Mller H H, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Unterhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, Arnold C N. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol: 2005; 3 761 771 (Pubitemid 41116728)
17. Pozsgai E, Schally A V, Halmos G, Rick F, Bellyei S. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res: 2010; 42 781 786
18. Sun W, Lipsitz S, Catalano P, Mailliard J A, Haller D G. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol: 2005; 23 4897 4904 (Pubitemid 46223995)
19. Dahan L, Bonnetain F, Rougier P, Raoul J L, Gamelin E, Etienne P L, Cadiot G, Mitry E, Smith D, Cvitkovic F, Coudert B, Ricard F, Bedenne L, Seitz J F. Fdration Francophone de Cancrologie Digestive (FFCD); Digestive Tumors Group of the Fdration Nationale des Centres de Lutte Contre le Cancer (FNCLCC) Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Rel Cancer: 2009; 16 1351 1361
20. Joseph K, Stapp J, Reinecke J, Skamel H J, Hffken H, Neuhaus C, Lenze H, Trautmann M E, Arnold R. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Horm Metab Res: 1993; 27 Suppl 28 35 (Pubitemid 23132616)
21. Fjllskog M L, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson E T. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol: 2003; 20 59 67 (Pubitemid 36344027)
22. Welin S, Fjllskog M L, Saras J, Eriksson B, Janson E T. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology: 2006; 84 42 48 (Pubitemid 44973686)
23. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol: 1993; 32 107 114 (Pubitemid 23188522)
24. Wulbrand U, Wied M, Zfel P, Gke B, Arnold R, Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest: 1998; 28 1038 1049 (Pubitemid 29050140)
25. von Wichert G, Jehle P M, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm B O, Adler G, Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res: 2000; 60 4573 4581 (Pubitemid 32103642)
26. Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman H. Presence of IGF-I in human midgut carcinoid tumours an autocrine regulator of carcinoid tumour growth? Int J Cancer: 1992; 51 195 203
27. Papouchado B, Erickson L A, Rohlinger A L, Hobday T J, Erlichman C, Ames M M, Lloyd R V. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol: 2005; 18 1329 1335 (Pubitemid 41348651)
28. Roussos E T, Condeelis J S, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer: 2011; 11 573 587
29. Terris B, Scoazec J Y, Rubbia L, Bregeaud L, Pepper M S, Ruszniewski P, Belghiti J, Fljou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology: 1998; 32 133 138 (Pubitemid 28126179)
30. Casanovas O, Hicklin D J, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell: 2005; 8 299 309 (Pubitemid 41443415)
31. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans D B, Vauthey J N, Xie K, Yao J C. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer: 2007; 109 1478 1486 (Pubitemid 46595681)
32. Pavel M E, Hassler G, Baum U, Hahn E G, Lohmann T, Schuppan D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf): 2005; 62 434 443
33. Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin M E, Meyer T. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer: 2009; 16 967 976
34. Detjen K M, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M, Scholz A. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res: 2010; 16 420 429
35. Figueroa-Vega N, Daz A, Adrados M, Alvarez-Escol C, Paniagua A, Aragons J, Martn-Prez E, Leskela S, Moreno-Otero R, Gonzlez-Amaro R, Marazuela M. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer: 2010; 17 897 908
36. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce C M, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol: 2010; 28 245 255
37. Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Rcken C, Wiedenmann B, Weichert W. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer: 2011; 18 181 192
38. Yao J C, Phan A, Hoff P M, Chen H X, Charnsangavej C, Yeung S C, Hess K, Ng C, Abbruzzese J L, Ajani J A. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol: 2008; 26 1316 1323
39. Kulke M H, Stuart K, Earle C C, Bhargava P, Clark J W, Enzinger P C, Meyerhardt J, Attawia M, Lawrence C, Fuchs C S. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol: 2006; 24 18S 4044
40. Kunz P, Kuo T, Zahn J M, Kaiser H L, Norton J A, Visser B C, Longacre T A, Ford J M, Balise R R, Fisher G A. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol: 2010; 28 15s (suppl; abstr 4104)
41. Venook A P, Ko A H, Tempero M A, Uy J, Weber T, Korn M, Bergsland E K. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol: 2008; 26 (suppl; abstr 15545)
42. Kulke M H, Chan J A, Meyerhardt J A, Zhu A X, Abrams T A, Blaszkowsky L S, Regan E, Sidor C, Fuchs C S. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol: 2011; 68 293 300
43. Varker K A, Campbell J, Shah M H. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol: 2008; 61 661 668
44. Kulke M H, Bergsland E K, Ryan D P, Enzinger P C, Lynch T J, Zhu A X, Meyerhardt J A, Heymach J V, Fogler W E, Sidor C, Michelini A, Kinsella K, Venook A P, Fuchs C S. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumor. J Clin Oncol: 2006; 24 3555 3561 (Pubitemid 46630526)
45. Pavel M E, Bartel C, Heuck F, Neumann F, Tiling N, Pape U F, Plckinger U, Wiedenmann B. Open-label, nonrandomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). Proc Am Soc Clin Oncol: 2008; 26 14684
46. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R A, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov: 2006; 5 835 844 Review. Erratum in: Nat Rev Drug Discov 2007; 6: 126 (Pubitemid 44480537)
47. Hobday T, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C. Sorafenib MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol: 2007; ASCO Annual Meeting Proceedings 2007; Part I. Vol 25, No. 18S (Suppl: 4504)
48. Castellano D E, Capdevila J, Salazar R, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Abad A, Sevilla I, Duran I. Spanish Neuroendocrine Tumor Group (GETNE). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol: 2011; 29 (suppl; abstr 4113)
49. Mendel D B, Laird A D, Xin X, Louie S G, Christensen J G, Li G, Schreck R E, Abrams T J, Ngai T J, Lee L B, Murray L J, Carver J, Chan E, Moss K G, Haznedar J O, Sukbuntherng J, Blake R A, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington J M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res: 2003; 9 327 337 (Pubitemid 36109749)
50. Kulke M H, Lenz H J, Meropol N J, Posey J, Ryan D P, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li J Z, Baum C M, Fuchs C S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol: 2008; 26 3403 3410
51. Raymond E, Dahan L, Raoul J-L, Bang Y J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen J S, Hrsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu D R, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med: 2011; 364 501 513
52. Raymond E, Niccoli P, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, Valle J W, Metrakos P, Smith D, Vinik A, Chen J, Hoersch D, Castellano D E, Kennecke H F, Picus J, Van Hazel G, Lu D, Chao R C, Patyna S, Van Cutsem E. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). J Clin Oncol: 2011; 29 (suppl; abstr 4008)
53. Phan A T, Yao J C, Fogelman D R, Hess K R, Ng C S, Bullock S A, Malinowski P, Regan E, Kulke M. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol: 2010; 28 15s (suppl; abstr 4001)
54. Hobday T J, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. ASCO Annual Meeting Proceedings 2006; Part I. Vol 24, No. 18S (Suppl): 4043
55. Reidy D L, Hollywood E, Segal M, Saltz L. A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). J Clin Oncol: 2010; 28 15s (suppl; abstr 4163)
56. Yao J C, Phan A T, Chang D Z, Wolff R A, Hess K, Gupta S, Jacobs C, Mares J E, Landgraf A N, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol: 2008; 26 4311 4318
57. Yao J C, Lombard-Bohas C, Baudin E, Kvols L K, Rougier P, Ruszniewski P, Hoosen S St., Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke M H, Hobday T J, ODorisio T M, Shah M H, Cadiot G, Luppi G, Posey J A, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol: 2010; 28 69 76
58. Yao J C, Shah M H, Ito T, Bohas C L, Wolin E M, Van Cutsem E, Hobday T J, Okusaka T, Capdevila J, de Vries E G, Tomassetti P, Pavel M E, Hoosen S, Haas T, Lincy J, Lebwohl D, berg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med: 2011; 364 514 523
59. Pavel M, Hainsworth J D, Baudin E, Peeters M, Hoersch D, Anthony L, Hoosen S St., Peter J, Jehl V, Yao J C. A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus + octreotide LAR vs. placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol: 2010; 21 08 viii1 viii12 LBA8
60. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol: 2002; 146 707 716 (Pubitemid 34552506)
61. Kvols L, Wiedenmann B, Oberg K, Glusman J E, Odorisio T M, De Herder W, Gao B, Arnold R, Anthony L. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J Clin Oncol: 2006; ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (Suppl): 4082
62. Kulke M H, Bergsland E K, Yao J C. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med: 2009; 360 195 197
63. Ong G S, Henley D E, Hurley D, Turner J H, Claringbold P G, Fegan P G. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol: 2010; 162 1001 1008
64. Fiebrich H B, Siemerink E J, Brouwers A H, Links T P, Remkes W S, Hospers G A, de Vries E G. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist: 2011; 16 783 787
65. Ferrer-Garca J C, Tolosa-Torrns M, Hernando-Meli C, Arribas-Palomar L, Snchez-Juan C. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract: 2011; 17 e17 e20
66. De Vries E, Anthony L B, Sideris L, Chen L, Lebrec J, Tsuchihashi Z, Winkler R E, Yao J C, berg K. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. J Clin Oncol: 2011; 29 (suppl; abstr 10624)
67. Baudin E, Wolin E M, Castellano D E, Kaltsas G, Lebrec J, Tsuchihashi Z, Klimovsky J, Saletan S, Yao J C, Gross D. Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results. J Clin Oncol: 2011; 29 (suppl; abstr 10527)
68. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki A T, Thomas G, Kozma S C, Papa A, Nardella C, Cantley L C, Baselga J, Pandolfi P P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest: 2008; 118 3065 3074
69. Zitzmann K, Rden J, Brand S, Gke B, Lichtl J, Spttl G, Auernhammer C J. Compensatory activation of Akt in response to mTOR and Raf inhibitors a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett: 2010; 295 100 109
70. Chiu C W, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol: 2010; 28 4425 4433
71. Grtzinger C. Tumour biology of gastroenteropancreatic neuroendocrine tumours. Neuroendocrinology: 2004; 80 01 8 11